• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down 80 Points; VirTra Shares Spike Higher

    4/3/23 2:48:14 PM ET
    $ASND
    $BPT
    $HSKA
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Integrated oil Companies
    Energy
    Get the next $ASND alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping around 80 points on Monday.

    The Dow traded up 0.89% to 33,571.43 while the NASDAQ fell 0.66% to 12,142.07. The S&P 500, also rose, gaining, 0.17% to 4,116.15.

    Check This Out: Top 4 Materials Stocks That Set To Fly In April

     

    Leading and Lagging Sectors

    • Energy shares jumped by 4.7% on Friday. Meanwhile, top gainers in the sector included Nine Energy Service, Inc. (NYSE:NINE), up 15%, and BP Prudhoe Bay Royalty Trust (NYSE:BPT), up 19%.
    • In trading on Friday, consumer discretionary fell by 1.4%.

     

    Top Headline

    The ISM manufacturing PMI fell to 46.3 in March versus a reading of 47.7 in February, missing market estimates of 47.5.

     

    Equities Trading UP

    • VirTra, Inc. (NASDAQ:VTSI) shares shot up 23% to $4.9373 after reporting a profit for the fourth quarter
    • Shares of Heska Corporation (NASDAQ:HSKA) got a boost, shooting 20% to $117.56 after Mars announced it would acquire the company for $120/share.
    • InterCure Ltd. (NASDAQ:INCR) shares were also up, gaining 25% to $2.55 after the company reported record fiscal year 2022 revenue of $150 million.

     

    Equities Trading DOWN

    • OncoSec Medical Incorporated (NASDAQ:ONCS) shares dropped 52% to $1.2413 after the company announced the primary endpoint of the overall response rate from the Phase 2 KEYNOTE-695 clinical trial was not met.
    • Shares of Palisade Bio, Inc. (NASDAQ:PALI) were down 34% to $2.3294 after the company announced a $6 million registered direct offering and concurrent private placement priced above the market under Nasdaq rules.
    • Ascendis Pharma A/S (NASDAQ:ASND) was down, falling 31% to $74.41 after the FDA identified deficiencies in the company's New Drug Application for Transcon PTH.

    Also Check This Out: Bitcoin Drops But Remains Above $28,000; Aptos Becomes Top Loser

     

    Commodities

    In commodity news, oil traded up 6.4% to $80.48 while gold traded up 0.8% at $2,001.80.

    Silver traded down 0.5% to $24.030 on Thursday while copper fell 1.2% to $4.0475.

    The Organization of the Petroleum Exporting Countries and its allies, known as OPEC+, trimmed oil production by 1.16 million barrels per day beginning May, in a surprising move.

     

    Euro zone

    European shares closed mixed today. The eurozone’s STOXX 600 fell 0.03%, London’s FTSE 100 rose 0.54% while Spain’s IBEX 35 Index fell 0.81%. The German DAX fell 0.31%, French CAC 40 rose 0.32% and Italy’s FTSE MIB Index gained 0.24%.

    The S&P Global Eurozone manufacturing PMI rose to 47.3 in March from a preliminary reading of 47.1. The S&P Global/CIPS UK manufacturing PMI rose to 47.9 in March versus the flash estimate of 48.0.

    German manufacturing PMI was revised higher to 44.7 in March versus a preliminary level of 44.4, while French manufacturing PMI fell to 47.3 in March from a preliminary estimate of 47.7.

     

    Asia Pacific Markets

    Asian markets closed higher on Monday, with Japan’s Nikkei 225 gaining 0.52%, Hong Kong’s Hang Seng Index climbing 0.04% and China’s Shanghai Composite Index gaining 0.72%. India’s S&P BSE Sensex gained 0.2%.

    The S&P Global India manufacturing PMI climbed to a three-month high of 56.4 in March. Retail sales in Australia rose by 0.2% month-over-month to AUD 35.14 billion for February. The au Jibun Bank Japan manufacturing PMI rose to 49.2 in March versus February’s reading of 47.7.

     

    Economics

    • The S&P Global manufacturing PMI slipped to 49.2 in March compared to the flash reading of 49.3.
    • The ISM manufacturing PMI fell to 46.3 in March versus a reading of 47.7 in February, missing market estimates of 47.5.
    • Construction spending fell by 0.1% month-over-month to an annual rate of $1.844 trillion in February.

    Now Read This: NVIDIA, Boston Scientific And This Technology Stock Insiders Are Selling

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 106,249,740 cases with around 1,155,320 deaths. India confirmed a total of at least 44,722,600 cases and 530,880 deaths, while France reported over 39,806,280 COVID-19 cases with 165,670 deaths. In total, there were at least 684,104,570 cases of COVID-19 worldwide with more than 6,832,410 deaths.

    Get the next $ASND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASND
    $BPT
    $HSKA
    $INCR

    CompanyDatePrice TargetRatingAnalyst
    Ascendis Pharma A/S
    $ASND
    1/28/2026$342.00Overweight
    Barclays
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Ascendis Pharma A/S
    $ASND
    11/18/2025$255.00Peer Perform
    Wolfe Research
    Ascendis Pharma A/S
    $ASND
    10/17/2025$271.00Strong Buy
    Raymond James
    Ascendis Pharma A/S
    $ASND
    7/3/2025$250.00Overweight
    Morgan Stanley
    Ascendis Pharma A/S
    $ASND
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    Ascendis Pharma A/S
    $ASND
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $ASND
    $BPT
    $HSKA
    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Ascendis Pharma with a new price target

    Barclays initiated coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $342.00

    1/28/26 7:15:39 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASND
    $BPT
    $HSKA
    $INCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Boudreau Alanna converted options into 3,278 shares, increasing direct ownership by 22% to 17,853 units (SEC Form 4)

    4 - VirTra, Inc (0001085243) (Issuer)

    12/12/25 4:05:20 PM ET
    $VTSI
    Miscellaneous manufacturing industries
    Consumer Discretionary

    $ASND
    $BPT
    $HSKA
    $INCR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nine Energy Service Inc.

    SCHEDULE 13G/A - Nine Energy Service, Inc. (0001532286) (Subject)

    2/6/26 5:54:44 PM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    Nine Energy Service Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Nine Energy Service, Inc. (0001532286) (Filer)

    2/6/26 6:03:39 AM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    SEC Form 25-NSE filed by Nine Energy Service Inc.

    25-NSE - Nine Energy Service, Inc. (0001532286) (Subject)

    2/5/26 10:37:03 AM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    $ASND
    $BPT
    $HSKA
    $INCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Givens John F. Ii bought $108 worth of shares (22 units at $4.92), increasing direct ownership by 0.01% to 328,388 units (SEC Form 4)

    4 - VirTra, Inc (0001085243) (Issuer)

    11/19/25 4:05:35 PM ET
    $VTSI
    Miscellaneous manufacturing industries
    Consumer Discretionary

    $ASND
    $BPT
    $HSKA
    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults

    MONTREAL, Feb. 6, 2026 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath®, was developed by Ascendis Pharma A/S (NASDAQ:ASND) ("Ascendis"). This approval follows the exclusive distribution agreement signed in July 2024 between Pendopharm and Ascendis Pharma, under which Pendopharm is responsible for the regulatory approval and commerc

    2/6/26 3:19:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026. The Company's virtual presentation is scheduled for Thur

    2/5/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

    COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma

    2/4/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    $BPT
    $HSKA
    $INCR
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VirTra Appoints Grant Barber to Advisory Board

    CHANDLER, Ariz., Nov. 04, 2025 (GLOBE NEWSWIRE) -- VirTra, Inc. (NASDAQ:VTSI) ("VirTra" or the "Company"), a global provider of judgmental use-of-force training simulators and firearms training systems, today announced the appointment of Grant A. Barber to its Advisory Board. Barber brings more than 35 years of international financial and operational leadership across technology, telecommunications, and industrial technology markets. Barber previously served as Executive Vice President and Chief Financial Officer at Hughes Communications, a global leader in satellite-based broadband and managed network services. During his tenure, he helped lead the company's transformation into a public

    11/4/25 8:00:00 AM ET
    $VTSI
    Miscellaneous manufacturing industries
    Consumer Discretionary

    $ASND
    $BPT
    $HSKA
    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Palisade Bio Inc.

    SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

    11/14/24 3:35:13 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 2:57:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    $BPT
    $HSKA
    $INCR
    Financials

    Live finance-specific insights

    View All

    Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

    COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma

    2/4/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

    – Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear growth – All children completed 52 weeks of treatment and remain on therapy in COACH as of today – Combination therapy was generally well tolerated, with generally mild treatment-emergent adverse

    1/8/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma Reports Third Quarter 2025 Financial Results

    –   Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® –   Q3 2025 operating profit of €11.0 million –   TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 –   Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. "With our achievements in the third quarter and year to date, Ascendis is making great progress toward achieving Vision 2030. The ongoing strong global launch of YORVIPATH

    11/12/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care